Anetumab ravtansine

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAnetumab ravtansine
Drug Alias NameBAY-94-9343-SPDB-DM4Anti-mesothelin antibody-drug conjugate BAY 94-9343BAY-94-9343
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-Mesothelin
TargetsMesothelinTubulin
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMorphosys AgBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesMorphosys AgNational Cancer InstituteBayer AG +[4] 
Inactive CompaniesYale University
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[7] 
Inactive IndicationsSolid tumoursLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A